# ResusSim — clinical review for Claude

**3 October 2026.** Reviewed all 19 items in continuity-clinical-review-2026-10-03.md against the intended continuity, oxygen-device and fluid features. This is a review of the supplied specification and reported test results; I have not inspected the implementation or rerun its tests.

**Overall verdict:** the device selection and finite-bag approach are useful improvements. Clinical continuity remains incomplete because H5 freezes important patient states during elapsed ward hours, while H2 substitutes fading offsets for some ongoing physiology. Correct H1–H3/H5, O7 and F1–F2 before treating the module as clinically consistent. F4 also needs an explicit PPV-validity safeguard.

Following the format requested in this attachment, every item receives a verdict, including acceptable assumptions. “Acceptable” means suitable within the stated teaching scope, not clinically validated. “Different value/logic” includes rules that need changing rather than replacing one coefficient. Numerical gains, time constants and software thresholds without direct validation are **expert opinion / simulation calibration**. Do not invent a guideline-backed replacement number where none exists.

## H — Handover and continuity

### H1 — Noradrenaline after handover

**Verdict: different value/logic. Priority: high.**

Keep **MAP 67 mmHg as an optional controller setpoint**, with an individualized prescribed range. Keep 0.5 µg/kg/min only as the **autonomous protocol limit**, followed by clinician reassessment; it is not a clinical maximum. The saturating effect curve and hourly dose increments are unvalidated calibration, not universal noradrenaline pharmacology.

Run unstable-patient reassessment on minute-scale substeps, or interrupt the course and return to active management. An hourly summary is acceptable; an hour without responding to deterioration is not. Weaning must depend on pressure and perfusion, rather than forcing a 10-hour trajectory. UI: **„Intensivmedizinischer Verlauf – Noradrenalin nach ärztlich angeordnetem Titrationsschema“**. Returning to the course screen must not imply transfer to an ordinary ward.

Do not classify the reported MAP ≥62 alone as unsafe: SSC 2026 allows practical variation around 65 and suggests an initial 60–65 range in patients ≥65 years. Judge against the chosen target and perfusion. Sources: [SSC 2026][SSC], [noradrenaline product information][NA].

### H2 — Fading effects

**Verdict: different value/logic. Priority: high.**

There is no defensible universal replacement for **τ = 6 h** or **τ = 2 h**. These are _differences from the course model_, not necessarily the actual volume effect or lactate concentration decaying toward zero/normal. Label them as model-reconciliation offsets if retained temporarily.

Preserve and advance actual fluid compartments, treatment effects and lactate state. Lactate should follow ongoing production/clearance; a fading offset must not remove congestion or cumulative fluid. Recalculate the oxygenation effect when ventilation, shunt, lung water or demand changes, even if the oxygen device is unchanged. **Unchanged support must not guarantee unchanged saturation benefit.** This is a model-consistency requirement, not a guideline-prescribed decay constant; expert opinion. Serial perfusion/lactate assessment: [SSC][SSC].

### H3 — Recurrent deterioration

**Verdict: clinically wrong if these are the sole escalation triggers. Priority: high.**

Trigger reassessment for persistent pressure below the **patient's prescribed range regardless of current noradrenaline dose**, rising support needs or worsening perfusion/respiratory status. Do not wait for the protocol maximum. Shock can exist without marked hypotension.

Replace **„Schock“** as a threshold-only label with **„Klinische Verschlechterung – sofortige Reevaluation erforderlich“**. The “once until MAP >70” latch can suppress a later serious event: deduplicate the same acknowledged episode, but re-alert for a meaningful new deterioration even if MAP never crossed 70. Dwell times/hysteresis are engineering choices requiring scenario checks, not diagnostic definitions. Source: [ESICM shock guidance 2025][SHOCK]; alert design is expert opinion.

### H4 — Clinical clock and paused organ indices

**Verdict: acceptable with explicit safeguards. Priority: medium.**

It is reasonable to pause a duplicate circulation/gas-exchange solver and its duplicate death check during a ≤30-minute episode. The workstation must remain responsible for deterioration/arrest/death, and relevant injury exposure must continue and be reconciled on return. Do not create 30 minutes without consequences from hypotension or hypoxemia.

Keep one absolute timestamp for administration, sampling, results and procedures; distinguish ordering from actual performance. **10:54:20** must remain the internal return time even if the UI displays 10:54. Results due during the episode must become available then. Slow indices may be updated coarsely, provided their elapsed exposure is counted once. Expert opinion / software consistency; no clinical guideline mandates a particular solver interval.

### H5 — Frozen patient between episodes

**Verdict: clinically wrong as described. Priority: high; principal continuity blocker.**

The patient identity should persist, but physiological time must advance. During elapsed course hours reconcile **delivered fluid and bag remainder, urine/losses, redistribution and congestion, drug administration and elimination/effect-site state, airway/support and respiratory changes**. Net fluid neutrality does not mean unchanged circulating volume or lung water.

An earlier sedative/opioid/relaxant effect must not reappear unchanged hours later; a running bag cannot remain full while its ward delivery is counted elsewhere. A reduced-step/background model is sufficient: continuous 100-ms waveform generation is unnecessary. If these states cannot yet be advanced, restrict unsupported handovers explicitly. Changing only vasoplegia, leak, temperature and noradrenaline does not establish clinical continuity. Expert opinion grounded in mass conservation and pharmacology.

## O — Respiratory support

### O1 — Device-dependent support

**Verdict: acceptable with scope and state safeguards. Priority: medium.**

Deferring T-piece/tracheostomy-mask support is acceptable. Say **„Spontanatmung über Tubus/T-Stück derzeit nicht abgebildet“**. Airway insertion must not itself abolish spontaneous drive, deliver breaths before circuit connection, or silently choose controlled ventilation. Keep airway type, connection and mode distinct; distinguish **„Tubus“** from **„Supraglottischer Atemweg“** rather than implying identical airway protection.

Standby disables ventilator-specific activity/alarms, not independent pulse-oximetry or apnea monitoring. Capnography without a tube is possible with suitable sampling equipment; its absence may be a scope limitation. Extubation with explicit next-support selection is appropriate. These are physiological/state-design safeguards; expert opinion. T-piece support is useful later but less urgent than H5/O7.

### O2 — Conventional oxygen estimates

**Verdict: acceptable approximate calibration. Priority: low.**

The listed directions are plausible. **Retain the 90% reservoir-mask cap**: BTS describes approximately 60–90% at 15 L/min, with variable performance. There is no reason to impose 80% as a universal ceiling. This does not validate every table entry or the 50/150/850-mL reservoir and efficiency constants.

Check that reservoir gas is a persistent, conserved store across breaths, not a fresh fixed volume granted every inspiration. Show **„FiO₂ geschätzt – abhängig von Atemmuster und Maskensitz“** and flag actual reservoir collapse. Exact percentages/reservoir coefficients remain expert-opinion calibration. Source for device range: [BTS oxygen guideline][BTS].

### O3 — Simple mask below minimum flow

**Verdict: acceptable provisionally; exact penalty unvalidated. Priority: low.**

Keep the **<5 L/min warning** and distinguish mask-on/no-flow from removing oxygen. BTS supports rebreathing risk, not a universal linear 100-mL dead-space penalty. The **0–100 mL surrogate may remain for one representative adult mask** as an explicit engineering assumption, with checks across tidal volume, respiratory timing, fit and washout. Do not claim it predicts a patient's PaCO₂ quantitatively.

UI: **„O₂-Flow unter Mindestfluss: Gefahr der CO₂-Rückatmung.“** No evidence-based replacement coefficient is available from the cited guidance. Source: [BTS][BTS]; surrogate approval is expert opinion.

### O4 — Venturi mask

**Verdict: acceptable table/equation; check the breath-mixing implementation. Priority: medium.**

The **24→2, 28→4, 31→6, 35→8, 40→10, 60→15 L/min** table exactly matches Intersurgical's published minimum-flow poster. Retain it as a **named device configuration**, not a universal German table. The ideal entrainment equation is correct. Allow increased inlet flow within device instructions: nominal FiO₂ remains the same while total flow rises. Source: [Intersurgical, June 2024][VENTURI].

If 26/32/38% are calculated by applying total-flow/peak-flow to the _entire_ inspiration, replace this with **inspiratory-volume-weighted mixing** using the available flow waveform. A brief peak shortfall does not last for the whole breath. The stated outputs reproduce a peak-based approximation; they are not reference FiO₂ values. This correction is a mathematical/modeling inference, not a new clinical formula recommendation.

### O5 — HFOT

**Verdict: different logic/scope; pressure coefficient may remain provisional. Priority: medium.**

Retain **0.04 cmH₂O per L/min** only as an explicitly approximate low-pressure calibration, not a validated mouth-open law. Account for mouth opening/fit; do not equate mean nasopharyngeal pressure with measured alveolar end-expiratory pressure. Apply O4's breath-weighted mixing check. Sources: [Parke 2011][HF_PRESSURE], [Li 2021][HF_FLOW].

**Apneic oxygenation is real.** For an anesthesia/airway simulator it should be represented, conditional on airway patency, preoxygenation, shunt and oxygen consumption. CO₂ must continue rising; oxygen does not replace ventilation. Until implemented, say **„Apnoeische Oxygenierung derzeit nicht abgebildet“** and do not teach that oxygen has no effect during apnea. Do not import a prolonged safe-apnea time from healthy elective patients into septic patients. Source: [Gustafsson 2017][APNEA].

### O6 — Unassisted breathing calibration

**Verdict: acceptable baseline; gains need validation. Priority: medium.**

**PaCO₂ 44 mmHg, saturation 95%, RR 14/min** are acceptable for a modeled healthy older adult; do not force everyone to 40/97. The 1.8 multiplier, 8%/mmHg gain and τ = 20 s remain **expert opinion**, not validated constants. Cross-check ventilation against CO₂ production/dead space and test body size, sedation and disease.

Keep **+3 cmH₂O only as an internal awake-recruitment surrogate**. It must not appear as measured PEEP or generate a positive-pressure cardiovascular effect; reduce it with loss of tone. Crucially, attaching NIV or changing the UI must not abruptly remove awake tone or the 1.8 gain while the patient remains physiologically unchanged. Hypoxic/hypercapnic drive must still be modulated by sedation and actual muscle capacity; sepsis scenarios also need appropriate metabolic-acidosis drive.

### O7 — Hypoxemia/congestion-driven breathing

**Verdict: clinically wrong as written. Priority: high.**

Do not switch this response off just because a ventilator is connected. Preserve it during **NIV, CPAP, pressure support and invasive modes with spontaneous activity**. Suppress effort when the modeled clinical state warrants it, such as paralysis/apnea or adequate suppression of drive. Support alters effort through unloading and gas exchange; it is not an on/off switch. Primary example of persistent effort during noninvasive support: [randomized physiological study, 2022][NIV_EFFORT].

The stated gains/thresholds remain expert opinion. Do not force effort ÷√rate for every hypoxemic state: rapid shallow breathing may emerge from stiffness/fatigue, whereas some patients increase both depth and rate. Show **„Erhöhte Atemarbeit“, „Einsatz der Atemhilfsmuskulatur“, „Sprechdyspnoe“** and exhaustion; a falling RR must not automatically mean improvement.

### O8 — Septic-episode starting support

**Verdict: acceptable scenario-specific default. Priority: medium.**

A simple mask at **6 L/min** is reasonable for a spontaneously breathing patient whose oxygen requirement it meets. Do not make it the default for all sepsis or overwrite transferred support. A normoxemic patient may need no oxygen; severe hypoxemia/critical instability needs appropriate escalation. The assigned saturation target and response determine suitability, not the diagnosis “sepsis.” Source: [BTS][BTS].

UI: **„Sauerstofftherapie aus der Übergabe übernommen“** for transferred patients. Initialize the 6-L/min configuration only for a new case explicitly written that way. “Strong drive” must also respect sedation, fatigue and neurological impairment.

## B — Infusion bags

### B1 — Nominal rates

**Verdict: acceptable game values. Priority: low.**

Retain **100 / 500 / 2,000 mL/h**. A 500-mL bag therefore lasts **5 h / 60 min / 15 min**. These are choices, not universal treatment recommendations. UI: **„Nominale Laufrate – Schwerkraftfluss vereinfacht“**.

Cannula/tubing limitations are a useful later refinement, but no blanket 20-G cap should be invented from gauge alone. Use actual manufacturer flow data plus tubing, pressure/head and fluid assumptions if adding such limits. The key requirement now is honest labeling and consistent delivered-volume accounting. Expert opinion / exact arithmetic.

### B2 — Empty-bag pause

**Verdict: acceptable in coached mode. Priority: low.**

Pause at every empty bag in coached mode; there is no clinical reason for a speed cutoff. Pause **all simulation clocks together**, and leave the bag empty until a new order. Later, an examination-mode option may alert while time continues; this must be an explicit mode choice.

UI: **„Beutel leer. Infusion beendet. Erneut anhängen / Verordnung ändern / Keine weitere Infusion“**. Show response and balance so that automatic repetition is not taught as the correct answer. Expert opinion / instructional design.

## F — Fluid response and congestion

### F1 — LV function and filling pressure

**Verdict: clinically wrong as a universal model; plausible only for a specified congested phenotype. Priority: high.**

A flatter systolic Frank–Starling response does not uniquely define diastolic stiffness or filling pressure. Preserved systolic function can coexist with high filling pressure; poor systolic function need not always mean congestion. Separate at least **contractility** from a **diastolic stiffness/filling-pressure phenotype**, and define the units and zero point of “volume status.” There is no justified universal replacement for **6, 0.3 or 20**. These remain calibration coefficients. Source for the phenotype distinction: [ESC HF guidance][HF].

Name the pressure surrogate consistently. Pulmonary capillary pressure, PAWP and LVEDP are not automatically interchangeable; clinically meaningful PAWP/LVEDP discordance is documented. [Hemnes 2018][WEDGE]. The internal LV-function scalar must not be labeled as an actual ejection fraction unless defined that way.

### F2 — Filling pressure and coronary supply

**Verdict: clinically wrong as the stated universal causal rule. Priority: high.**

Reducing the penalty avoids one undesirable run but does not validate **−1.5%/mmHg above 15 with a 50% floor**. As a simplified starting point, LV subendocardial driving pressure depends on **aortic diastolic pressure minus LVEDP**, with diastolic duration, oxygen content, demand and coronary disease also relevant. A pulmonary-pressure threshold alone is insufficient. This is physiological modeling advice, not a validated VF-prediction equation; [primary disease-specific physiological evidence][CORONARY] illustrates the relationship, not these coefficients.

Until that pathway is credible, remove the **pulmonary-pressure-only trigger for VF** and preserve congestion/hypoxemia consequences. Arrhythmia can still arise through independently justified severe ischemia, hypoxemia or other mechanisms. Do not claim VF within an hour is impossible or assign a frequency unsupported by data. An overdose regression test passing is not clinical validation.

### F3 — Reported fluid-response trajectories

**Verdict: acceptable directions; magnitudes not clinically validated. Priority: medium.**

The responder/nonresponder contrast and oxygen masking desaturation while congestion persists are useful. Treat these as example runs, not clinical calibration targets. Compare **fluid and no-fluid at the same timestamp with identical other conditions in every row**; the vasoplegia row's before→after notation is ambiguous.

The CO changes are **+11.1%** for 4.06→4.51 and **+2.6%** for 3.08→3.16. A 3-mmHg MAP rise is possible if vascular resistance or other conditions change. With unchanged RAP/CVP and SVR, however, **MAP ≈ RAP + CO×SVR/80** (SVR in dyn·s·cm⁻⁵) constrains the response: for example, at RAP 5 mmHg, the stated CO change predicts **MAP 64→about 70.5 mmHg**. Log SVR and RAP to explain the smaller rise; do not force either increment as a rule. This is an arithmetic consistency check.

Define the dimensionless lung-water ratio; it is not automatically EVLWI. Persistent edema 10 minutes after stopping fluid is plausible, but **98% retention is not a universal clearance rule**. Include urine/losses and outputs when checking mass balance. Expert opinion / model validation.

### F4 — What the learner can assess

**Verdict: different logic if PPV lacks validity guards; PLR is a high-value next feature. Priority: high.**

Keep inaccessible hidden physiology out of routine monitoring. **PPV must be flagged as unreliable for fluid-responsiveness assessment during spontaneous breathing or arrhythmia**, with additional limitations from low tidal volume/compliance, low HR/RR ratio, RV dysfunction and other relevant conditions. UI: **„PPV zur Beurteilung der Volumenreagibilität derzeit nicht zuverlässig“**. Verify whether these guards already exist before treating this as a confirmed code defect. [DGAI 2024][DGAI].

Add PLR with rapidly responsive **CO/SV or appropriately measured LVOT-VTI**, baseline→maneuver→return. A rise of about **10% in CO** is a reasonable teaching threshold, with an uncertainty zone rather than false precision; MAP alone is insufficient. [Original PLR study][PLR]. Fluid responsiveness does **not** itself establish a need for fluid: consider hypoperfusion and tolerance. [DGAI][DGAI].

## Five teaching points to add next

1. **Oxygen prescription and reassessment:** an explicit target, titration down after recovery, blood gases when needed and hypercapnia risk. If retaining German S3 2021 targets such as 92–96% for nonventilated adults without hypercapnia risk and 88–92% with risk, identify that edition and scope. The AWMF oxygen document is now marked expired/under revision; do not label it a new 2026 recommendation. [AWMF source/status][O2DE].
2. **Oxygenation versus ventilation:** opioid-related hypoventilation/apnea can coexist with reassuring SpO₂ on oxygen. Teach consciousness, breathing and CO₂ assessment, airway management and assisted ventilation; distinguish apneic oxygenation from ventilation. [APNEA][APNEA].
3. **HFOT/NIV failure:** persistent work of breathing, fatigue, impaired consciousness, acidosis or deteriorating circulation can require escalation despite acceptable SpO₂. A lower RR caused by exhaustion is not success. [NIV physiology][NIV_EFFORT]; scenario design is expert opinion.
4. **Response versus tolerance over time:** contrast a hypovolemic responder with congested HFpEF/LV or RV dysfunction; include renal impairment, ongoing losses and reassessment after each intervention. Later introduce appropriate de-resuscitation rather than repeated fluid for oliguria alone. [DGAI][DGAI], [SSC][SSC].
5. **Delivery-system failures:** disconnected oxygen, collapsed reservoir/poor mask fit, empty cylinders, clamped IV lines and paused/empty bags. The order, displayed setting and volume/gas actually delivered must be distinguishable. Expert-opinion scenario design.

## Focused acceptance evidence to return with the next revision

These are requested checks, not tests performed by this reviewer.

- H5: compare a continuous-control run with a several-hour course interval containing a partial bag, a stopped sedative and ongoing urine loss; re-entry must not restore obsolete states. Repeat inside campaign and across save/load.
- H1/H3: deterioration below the individualized target at a dose below the autonomous ceiling still triggers timely action; a second worsening event is not suppressed by the MAP 70 latch.
- H2/F3: unchanged oxygen support plus increasing congestion can worsen oxygenation/effort; a fading offset does not clear actual lung water or delivered-volume history.
- O1/O6/O7: an awake patient switching mask→NIV retains appropriate spontaneous drive without an unexplained gain/FRC jump; spontaneous activity is possible with an artificial airway and suitable mode.
- O4/O5: compare peak-based and breath-integrated delivered FiO₂ using actual inspiratory waveforms and a finite gas reservoir; preserve oxygen mass balance.
- F1/F2: include preserved-contractility/high-stiffness and reduced-contractility/noncongested states; no isolated fluid-volume/PC-pressure threshold directly produces VF.
- F3/F4: report matched-time fluid/no-fluid CO, MAP, CVP/RAP and SVR; verify PPV validity flags and, when added, reversible PLR responses.

## Sources

Sources support the particular clinical statements cited; they do not validate the simulator's coefficients. Product-specific values apply to the named device/product. Older physiological studies are used for mechanisms, not as new treatment guidelines.

[SSC]: https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-campaign-international-guidelines-for-management-of-sepsis-and-septic-shock-2026
[NA]: https://www.medicines.org.uk/emc/product/13172/smpc
[SHOCK]: https://www.esicm.org/wp-content/uploads/2025/10/Visual-abstract-final.pdf
[BTS]: https://www.brit-thoracic.org.uk/document-library/guidelines/emergency-oxygen/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings/
[VENTURI]: https://www.intersurgical.com/content/files/116942/-435354333
[HF_PRESSURE]: https://pubmed.ncbi.nlm.nih.gov/21496369/
[HF_FLOW]: https://link.springer.com/article/10.1186/s13613-021-00949-8
[APNEA]: https://pubmed.ncbi.nlm.nih.gov/28403407/
[NIV_EFFORT]: https://pmc.ncbi.nlm.nih.gov/articles/PMC9023341/
[HF]: https://academic.oup.com/eurjhf/article/24/1/4/8364349
[WEDGE]: https://pubmed.ncbi.nlm.nih.gov/30148982/
[CORONARY]: https://www.journalofcmr.com/article/S1097-6647%2824%2901675-2/fulltext
[DGAI]: https://link.springer.com/article/10.1007/s10877-024-01132-7
[PLR]: https://pubmed.ncbi.nlm.nih.gov/16540963/
[O2DE]: https://register.awmf.org/assets/guidelines/020-021k_S3_Sauerstoff-in-der-Akuttherapie-beim-Erwachsenen_2021-11_2-abgelaufen.pdf

- **HF reference:** ESC 2021 phenotype definitions are cited for preserved systolic function with elevated filling pressure, not as a review of current heart-failure drug treatment.
- **Coronary reference:** Bennett et al., JCMR 2025, supplement abstract 101648, concerns aortic stenosis; this limited primary evidence does not provide a universal pressure penalty or VF risk estimate.
- **Oxygen-guideline status:** AWMF lists the prior extension through 31 May 2026 and now supplies an expired version pending revision: [AWMF notice](https://www.awmf.org/aktuelles/awmf-aktuell/sauerstoff-in-der-akuttherapie-beim-erwachsenen).
